Litcius/Paper detail

Increased <i>bla</i> <sub>KPC</sub> Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate

Paolo Gaibani, Gabriele Bianco, Stefano Amadesi, Matteo Boattini, Simone Ambretti, Cristina Costa

2022Antimicrobial Agents and Chemotherapy44 citationsDOIOpen Access PDF

Abstract

Herein, we report the in vivo evolution of imipenem/relebactam-resistance in KPC-producing K. pneumoniae (KPC-Kp) isolated from a critically-ill patient treated with multiple combination therapies based on ceftazidime-avibactam or meropenem-vaborbactam. Imipenem/relebactam-resistance was associated to meropenem-vaborbactam cross-resistance and was due to truncated OmpK35 and OmpK36 porins and increased copy of bla KPC copy number.

Topics & Concepts

MeropenemKlebsiella pneumoniaeImipenemMicrobiologyBiologyKlebsiellaVirologyAntibiotic resistanceAntibioticsGeneticsGeneEscherichia coliAntibiotic Resistance in BacteriaInfections and bacterial resistanceMycobacterium research and diagnosis
Increased <i>bla</i> <sub>KPC</sub> Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate | Litcius